- Amivantamab plus lazertinib vs osimertinib as first-line treatment among Asian patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup analysisLu, S.; Cho, B. C.; Lee, J-S.; Lee, S-H.; Danchaivijitr, P.; Liu, B.; Alip, A.; Xiong, H.; How, S. H.; Chang, G-C.; Yang, J. C-H.; Yoshioka, H.; Xia, K.; Martinez, M.; Bauml, J. M.; Sethi, S.; Hayashi, H.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
- Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced nonsmall cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trialCho, B. C.; Felip, E.; Spira, A. I.; Girard, N.; Lee, J. S.; Lee, S. H.; Ostapenko, Y. V.; Danchaivijitr, P.; Liu, B.; Alip, A.; Korbenfeld, E. P.; Dias, J.; Sun, T.; Martinez, M.; Bauml, J. M.; Shreeve, M.; Sethi, S.; Knoblauch, R. E.; Hayashi, H.; Lu, S.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.被引 2
- First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohortCheng, Y.; Yu, Y.; Fan, Y.; Jiang, L.; Wu, L.; Hu, J.; Wang, J.; Yao, W.; Han, Z.; Yao, Y.; Fang, J.; Sun, M.; Wang, Q.; Pan, Y.; Wu, R.; Liu, J.; Liu, Y.; Kulkarni, D.; Huang, X.; Janne, P. A.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
会议论文
Tepotinib plus osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinib
8阅读
